Nosis Bio, a startup developing new ways to deliver RNA therapies to specific cells, has struck partnerships with two pharma ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

AstraZeneca (NASDAQ:AZN) said on Friday that its gastric cancer treatment, IMFINZI, demonstrated a statistically significant ...

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

The 15 th World Clinical Biomarkers & Companion Diagnostics Summit Europe (8-10 th April, London) is an important event for advancing precision treatments in the European market. Check out a sneak ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...